PPG Sells Traffic Equipment Manufacturer Eberle Design, Inc.

PITTSBURGH--(BUSINESS WIRE)-- PPG (NYSE: PPG) today announced that it has completed the divestiture of Eberle Design, Inc. (EDI) to Vance Street Capital. Terms of the transaction were not disclosed.

EDI is a leading manufacturer of electronic control system components used for managing traffic safety and detecting vehicles at intersections, and for parking and access, rail, and emergency vehicle applications. The company has approximately 150 employees and operates from a single location in Phoenix, Arizona. Vance Street will incorporate EDI into its Intelligent Transportation Systems (ITS) platform, which includes Polara Enterprises and Carmanah Technologies.

PPG acquired EDI in December 2020, along with the Ennis-Flint business. Ennis-Flint remains the core of PPG’s Traffic Solutions business unit and is not impacted by the sale of EDI.

PPG: WE PROTECT AND BEAUTIFY THE WORLD™

At PPG (NYSE: PPG), we work every day to develop and deliver the paints, coatings and materials that our customers have trusted for nearly 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 75 countries and reported net sales of $16.8 billion in 2021. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.

We protect and beautify the world is a trademark and the PPG Logo is a registered trademark of PPG Industries Ohio, Inc.

CATEGORY Corporate

View source version on businesswire.com: https://www.businesswire.com/news/home/20220614005316/en/

Media Contact:
Mark Silvey
Corporate Communications
+1-412-434-3046
[email protected]

Investor Contact:
John Bruno
Investor Relations
+1-412-434-3466
[email protected]
investor.ppg.com

Source: PPG

You May Also Be Interested In

• AM Best Affirms Credit Ratings of Tower Limited
• TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
• LENSRXLAB Introduces Groundbreaking Vision Benefits Platform Catered to Diabetic Individuals